MMM

Read This to Understand 3M Company Stock

It's been a great afternoon session for 3M Company investors, who saw their shares rise 1.4% to a price of $103.97 per share. At these higher prices, is the company still fairly valued? If you are thinking about investing, make sure to check the company's fundamentals before making a decision.

The Market May Be Overvaluing 3M Company's Earnings and Assets:

3M Company provides diversified technology services in the United States and internationally. The company belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 30.21 and an average price to book (P/B) ratio of 4.08. In contrast, 3M Company has a trailing 12 month P/E ratio of -7.8 and a P/B ratio of 12.29.

3M Company has moved -18.7% over the last year compared to 16.2% for the S&P 500 — a difference of -34.9%. 3M Company has a 52 week high of $129.9 and a 52 week low of $85.35.

Shareholders Are Confronted With a Declining EPS Growth Trend:

2018 2019 2020 2021 2022 2023
Revenue (MM) $32,765 $32,136 $32,184 $35,355 $34,229 $32,747
Revenue Growth n/a -1.92% 0.15% 9.85% -3.18% -4.33%
Operating Margins 22% 19% 22% 21% 19% 20%
Net Margins 16% 14% 17% 17% 17% 0%
Net Income (MM) $5,363 $4,529 $5,458 $5,929 $5,791 $16
Net Interest Expense (MM) $350 $448 $529 $488 $462 $686
Depreciation & Amort. (MM) $1,488 $1,593 $1,911 $1,915 $1,831 $1,910
Earnings Per Share $8.89 $7.72 $9.36 $10.12 $10.18 -$13.32
EPS Growth n/a -13.16% 21.24% 8.12% 0.59% -230.84%
Diluted Shares (MM) 602 585 582 585 568 511
Free Cash Flow (MM) $4,862 $5,371 $6,612 $5,851 $3,842 $4,853
Capital Expenditures (MM) $1,577 $1,699 $1,501 $1,603 $1,749 $1,763
Current Ratio 1.89 1.41 1.89 1.7 1.54 1.05
Total Debt (MM) $15,367 $22,154 $19,589 $16,276 $14,843 $16,013
Net Debt / EBITDA 1.44 1.86 1.65 1.26 1.34 1.31
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS